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Abstract
Neuromyelitis optica (NMO) is an autoimmune disease of the CNS that is characterized by 
inflammatory demyelinating lesions in the spinal cord and optic nerve, potentially leading to 
paralysis and blindness. NMO can usually be distinguished from multiple sclerosis (MS) on the 
basis of seropositivity for IgG antibodies against the astrocytic water channel aquaporin-4 
(AQP4). Differentiation from MS is crucial, because some MS treatments can exacerbate NMO. 
NMO pathogenesis involves AQP4-IgG antibody binding to astrocytic AQP4, which causes 
complement-dependent cytotoxicity and secondary inflammation with granulocyte and 
macrophage infiltration, blood–brain barrier disruption and oligodendrocyte injury. Current NMO 
treatments include general immunosuppressive agents, B-cell depletion, and plasma exchange. 
Therapeutic strategies targeting complement proteins, the IL-6 receptor, neutrophils, eosinophils 
and CD19—all initially developed for other indications—are under clinical evaluation for 
repurposing for NMO. Therapies in the preclinical phase include AQP4-blocking antibodies and 
AQP4-IgG enzymatic inactivation. Additional, albeit currently theoretical, treatment options 
include reduction of AQP4 expression, disruption of AQP4 orthogonal arrays, enhancement of 
complement inhibitor expression, restoration of the blood–brain barrier, and induction of immune 
tolerance. Despite the many therapeutic options in NMO, no controlled clinical trials in patients 
with this condition have been conducted to date.
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Introduction
Neuromyelitis optica (NMO) is a rare inflammatory demyelinating disease of the CNS, with 
a predilection for the optic nerves and spinal cord. NMO was thought to be a variant of 
multiple sclerosis (MS), but in 2004, a serum antibody specific to patients with NMO was 
detected.1 This antibody, initially termed NMO-IgG, was subsequently shown to recognize 
extracellular conformational epitopes of the astrocytic water channel protein aquaporin-4 
(AQP4).2 NMO-IgG—later named AQP4-IgG (or AQP4-Ab)—has a key role in the 
pathogenesis of NMO.3
The currently used diagnostic criteria for NMO—the revised Wingerchuk 2006 criteria4—
incorporate the presence of AQP4-IgG. These criteria comprise two absolute criteria (optic 
neuritis and acute transverse myelitis) and three supportive criteria (brain MRI not meeting 
criteria for MS at disease onset, spinal cord MRI with contiguous T2-weighted signal 
abnormality extending over three or more vertebral segments, and AQP4-IgG-seropositive 
status). The diagnosis of NMO requires the presence of two absolute criteria and at least two 
of the three supportive criteria. Patients with NMO who have AQP4-IgG antibodies are 
referred to as seropositive (AQP-IgG+) and those without are seronegative (AQP4-IgG−). 
Seropositive patients who do not fulfil enough conditions to satisfy the diagnostic criteria of 
NMO are said to have NMO spectrum disorder (NMOSD). With improved understanding of 
NMO pathogenesis, the Wingerchuk criteria are being revised; the new criteria will be 
published in 2014.
The epidemiology of NMO is not clearly established, because NMO is often misdiagnosed 
as MS. Reported prevalence ranges from 0.1–4.4 cases per 100,000.5–7 The mean age at 
presentation is 34–43 years, although children and older adults are also affected.8–12 Patients 
with AQP4-IgG+ NMO have a marked female predominance with reported female:male 
ratios of about 10:1 in Japanese9 and white10 populations.
Various autoimmune diseases have been reported in up to 30% of patients with NMO,13 
suggesting that individuals with this condition might have a genetic predisposition to 
aberrant autoimmunity. AQP4 mutations do not account for susceptibility to NMO.14 
Although some studies have reported associations between HLA alleles and NMO,15–17 
others have found no association,18 suggesting a complex, multifactorial genetic 
susceptibility, with only 3% of patients with NMO having relatives with this condition.19
Individuals of African and East Asian origin have a higher risk of NMO than MS, whereas 
in white populations, MS is about 40 times more common than NMO.5,20–22 Distinguishing 
NMO from MS is clinically important because the treatments differ and, importantly, some 
MS treatments, such as IFN-β, natalizumab and oral fingolimod, can exacerbate NMO.
In this Review, we outline the pathogenetic mechanisms of NMO and discuss currently 
available pharmacological therapies, as well as therapies that have potential for repurposing 
in NMO. Furthermore, we review the therapies that are currently being developed.
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Pathology
The working hypothesis for NMO pathogenesis involves entry of AQP4-IgG into the CNS 
and binding to AQP4 on perivascular astrocyte endfeet, which causes activation of the 
classical complement cascade with an inflammatory response that leads to marked 
granulocyte and macrophage infiltration, causing secondary oligodendrocyte damage, 
demyelination and neuronal death (Figure 1). The evidence in support of this mechanism, as 
discussed in recent reviews on the subject,12,23–25 comes from pathology of human NMO 
lesions, and a substantial body of in vitro and animal model data.
The events initiating AQP4-IgG production and its access to the CNS remain unclear; 
speculations have included AQP4 molecular mimicry,26 precipitating infection, 27 and 
circulating blood–brain barrier permeabilizing factors.28 Two independent studies29,30 have 
proposed an extrathecal origin of AQP4-IgG in NMO. Recent data suggest that AQP4-IgG-
producing plasmablasts from the periphery might enter the CNS, creating foci of 
inflammation. 31 The relative contribution of extrathecal versus intrathecal AQP4-IgG 
production during an NMO attack is, therefore, unclear. The central involvement of AQP4-
IgG binding to AQP4 on astrocytes and complement-dependent cytotoxicity (CDC) in NMO 
lesion formation is strongly supported by experimental data,3,32–34 as is the involvement of 
infiltrating granulocytes and macrophages.35–37 Recent data also indicate the importance of 
antibody-dependent cellular cytotoxicity (ADCC) in NMO pathogenesis.38
The precise mechanisms by which the inflammatory cascade in NMO produces 
oligodendrocyte injury and demyelination, possibly quite early in the disease process, 
remain unclear.39 The role of T cells—which, in addition to their involvement in initial 
AQP4-IgG generation, might be involved along with other factors in permeabilization of the 
blood–brain barrier—is also not well understood,40 but current data suggest that these cells 
are probably not involved in the progressive stage of NMO lesion pathology.41,42 Various 
propositions for alternative NMO pathogenesis mechanisms, such as excitotoxic injury,43 
AQP4-IgG-mediated inhibition of AQP4 water permeability and AQP4-induced AQP4 
aggregation,44 are controversial in light of the more-recent data.45,46 Interestingly, 
transgenically induced destruction or dysfunction of astrocytes exacerbates inflammation 
and demyelination in mice.47,48 The contributions of AQP4-IgG-mediated loss of astrocyte 
function to NMO pathogenesis are understudied and could present novel treatment 
opportunities.
Current therapies
Two consensus papers on the treatment of NMO have been published by panels of experts in 
the field.49,50 The overall rationale of NMO therapy is to minimize neurological disability 
by ameliorating acute attacks and preventing future exacerbations (Table 1). Acute therapies 
are designed to minimize injury and accelerate recovery, whereas preventative therapies are 
focused on reducing attack frequency and severity. Since disease progression in the absence 
of clinical relapse is rare in NMO,51 beneficial treatments will limit the accumulation of 
permanent neurological injury in affected individuals.
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Treatment of acute attacks
Intravenous methylprednisolone (IVMP) and plasma exchange comprise the standard 
treatments for acute disease exacerbations in NMO. These therapies have been co-opted 
from the treatment of acute demyelinating attacks in MS, transverse myelitis and optic 
neuritis. Corticosteroids have a myriad of anti-inflammatory and immunosuppressive 
effects, including reduction in circulating lymphocytes and monocytes; decreased expression 
of cell adhesion molecules and metalloproteinases; and altered transcription of 
proinflammatory cytokines.52 Interestingly, T-helper cell 17 (TH17) cytokines such as 
IL-17A, IL-6 and IL-23p19,53,54 the levels of which are elevated during NMO 
exacerbations, are downregulated by corticosteroids.55 In addition to a direct role in 
removing pathogenic AQP4-IgG, plasma exchange could similarly reduce levels of 
proinflammatory cytokines, alter the numbers of T cells and B cells, and modify TH-cell 
phenotypes.56
No prospective therapeutic trials for acute NMO exacerbations exist to date, meaning that 
optimal dosages, duration and sequence for acute therapy have not been established. In 
general, IVMP (1 g) is delivered daily for 3–5 days and, if the symptoms do not clearly 
improve, plasma exchange is administered daily or every other day for up to five treatments. 
If plasma exchange has been successfully used in the past in an individual patient, it can also 
be considered as a first-line treatment for acute relapse. Although retrospective studies and 
case series have reported marked improvement in visual and neurological function in 
patients with NMO following plasma exchange,57,58 improvement was independent of 
AQP4-IgG seropositivity.58
Male sex, preserved reflexes and early initiation of therapy have been found to increase the 
likelihood of improvement in response to plasma exchange.59 A recent retrospective study 
showed that rapid sequencing or concurrent use of plasma exchange with IVMP resulted in 
better visual acuity, improved visual fields, and greater retinal nerve fibre layer preservation 
as measured by optical coherence tomography.60 Hence, any delay in neurological 
improvement following IVMP therapy should prompt consideration of rapid initiation of 
plasma exchange. Additional case series have reported benefits of IVIg therapy61 and 
cyclophosphamide infusion62 in patients with NMO.
Prevention of attacks
Due to the high morbidity associated with NMO exacerbations, immunosuppressive therapy 
is typically instituted after the first attack. Unfortunately, interventional studies with level I 
or II evidence are not yet available; therefore, treatment decisions are typically made after 
balancing the best available data on clinical efficacy, short-term and long-term adverse 
effects, comorbid conditions, disease-associated risk factors, functional status, and prior 
treatment. Possible predictors of disability in NMO patients include male sex, Afro-
Caribbean or Asian ethnicity, young age at onset,63 motor symptoms or tetraparesis at first 
myelitis attack, and more than one myelitis attack in the first year.10
Active NMO lesions demonstrate antibody-mediated and cell-mediated immunopathology. 
As a result, current preventative therapies are used to deplete immune cell populations, 
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diminish circulating AQP4-IgG, or interfere with immune cell proliferation or activation. 
Interestingly, the most commonly used agents, azathioprine, mycophenolate and rituximab, 
primarily target lymphocytes and seem to diminish disease activity without consistent 
effects on AQP4-IgG titre. The clinical response suggests that lymphocytes might promote 
disease activity through diverse and complex roles, including antigen presentation, 
proinflammatory cytokine production, and altered regulatory immune networks.
Corticosteroids and plasma exchange—In addition to their use in the treatment of 
acute exacerbations, oral corticosteroids and plasma exchange can be used on a chronic 
basis for prophylactic therapy. Low-dose oral prednisolone (2.5–20.0 mg daily) was 
evaluated retrospectively in a cohort of 25 patients over a median observation period of 19.3 
months.64 Treatment success showed a dose-dependent relationship; doses greater than 10 
mg daily were significantly more efficient than lower doses. Low dose corticosteroid 
decreased the median annualized relapse rate (ARR) from 1.48 to 0.49.64 Regular plasma 
exchange treatment in association with additional immunosuppression has also shown 
benefit in reducing relapse activity.65
Azathioprine—Azathioprine is converted to nucleotide antimetabolites that interfere with 
lymphocyte proliferation. A retrospective study of 99 patients with NMO or NMOSD 
demonstrated an ARR reduction from 2.20 to 0.52 relapses over a median treatment interval 
of 22 months.66 Improvement was noted to be greater in patients receiving doses larger than 
2 mg/kg daily, and in those showing an increased erythrocyte mean cell volume. The main 
reasons for discontinuation of therapy included lack of efficacy, systemic adverse effects 
and lymphoma. Two smaller studies of azathioprine have reported similar results.67,68 ARR 
was reduced by more than 50% by use of moderate to high dosages of azathioprine (2–3 
mg/kg daily), with or without concurrent steroids. Due to a delay in therapeutic effect (3–6 
months), therapy is often initiated in combination with corticosteroids.
Mycophenolate mofetil—Mycophenolate mofetil, a prodrug of the active metabolite 
mycophenolic acid, suppresses lymphocyte proliferation by inhibiting guanosine nucleotide 
biosynthesis. In a retrospective study of 24 patients, a reduction in the median ARR from 
1.28 to 0.09 over a median follow-up of 28 months (median dose 2 g daily) was observed.69 
Disability remained relatively unchanged. 19 patients remained on medication, 25% of 
patients noted adverse events, and one patient died of disease complications.
Methotrexate—Methotrexate inhibits folate-dependent enzymes and interferes with purine 
and thymidylate synthesis. 14 AQP4-IgG-seropositive patients with NMO or NMOSD 
treated with methotrexate (median dose: 17.5 mg weekly; median duration: 21.5 months) 
showed a significant reduction in the median ARR from 1.39 before treatment to 0.18 during 
treatment.70 Nearly half of the patients were relapse-free, and none discontinued therapy. 
However, 13 of the 14 patients were co-treated with prednisolone, tacrolimus or rituximab, 
the impact of which is unknown. In an earlier case series, seven NMO patients treated with 
methotrexate (50 mg weekly) and oral prednisolone (1 mg/kg daily) demonstrated disease 
stabilization, as measured by disease activity and the expanded disability status scale 
(EDSS).
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Mitoxantrone—Mitoxantrone inhibits topoisomerase II, suppresses lymphocyte and 
macrophage development, and inhibits B-cell activation. 20 patients with NMO or NMOSD 
treated with mitoxantrone (three to six monthly cycles of 12 mg/m2 followed by 6–12 
mg/m2 maintenance doses) for an average of 17 months showed a reduction in ARR (2.8 
before treatment to 0.7 after treatment) and mean EDSS score (5.6 to 4.4).71 In another 
small case series, four of five patients with NMO showed clinical benefit and three of five 
patients became relapse-free.71 A significant decline in left ventricular ejection fraction was 
observed in one patient after a cumulative dose of 72 mg/m2. Mitoxantrone-related 
leukaemia, a serious consequence of treatment, has not been reported in any NMO patient, 
probably owing to the low number of patients treated with mitoxantrone to date.
Cyclophosphamide—Cyclophosphamide is a cytotoxic alkylating agent that is used in 
the treatment of severe autoimmune disorders. This drug has been evaluated in NMO in two 
small clinical case series, with differing results. One small study of four patients with 
NMOSD reported a reduction in median EDSS score from 8.0 to 5.75;72 by contrast, no 
improvement in relapse rate or disability was observed in another study of seven patients 
with NMO.73
Rituximab—Rituximab is a chimaeric anti-CD20 monoclonal antibody that depletes both 
naive and memory B cells. Multiple dosing regimens have been explored for NMO 
rituximab therapy. In most studies, rituximab was administered at regular 6-month intervals 
beginning with four weekly doses of 375 mg/m2 followed by two biweekly doses of 1 
g.74–78 Other studies used more-frequent infusions (usually 1 g every 12 months)77 or 
administration depending on circulating B-cell numbers.74–76,79 In each study, patients 
treated with rituximab demonstrated a significant reduction in ARR, and stabilization of 
disability. In general, the reduction in ARR was substantial—in two studies, the post-
treatment ARR was zero. EDSS scores stabilized or improved in most patients.75,77–79
To date, no definitive biomarker of disease activity has emerged in rituximab-treated 
individuals. According to one study, AQP4-IgG titres and CD19+ B-cell counts rise before 
relapse and fall with remission,80 whereas another study suggests that the suppression of 
disease activity by rituximab correlates with the extent of B-cell depletion, but not with 
serum AQP4-IgG titre or serum levels of B-cell-activating factor (BAFF) or a proliferation-
inducing ligand.81 Additional studies are needed to determine whether the benefits of 
CD20+ B-cell depletion are mediated by a reduction in AQP4-IgG production or through 
effects on other proinflammatory B cell functions.82 Most of the serious adverse events were 
attributable to disease relapse; however, severe infections and cardiovascular failure were 
also reported. Progressive multifocal leukoencephalopathy has been reported in rituximab-
treated patients (though not yet in NMO), and can present a potential limitation, especially 
in combination therapies.83
Combination therapies—Combination therapy with cytotoxic, immunomodulatory, and 
B-cell-depleting therapies is a fundamental approach to the treatment of many autoimmune 
disorders such as rheumatoid arthritis. In NMO, the rarity of disease, the risk of infectious 
complications, and the cost of therapeutics have limited the employment of combination 
therapy. To date, the use of combination therapy in NMO has been limited to oral 
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corticosteroids (prednisolone or prednisone) plus immunosuppressive agents such as 
azathioprine66 and cyclosporine;84 combination of corticosteroids with both azathioprine 
and cyclosporine have demonstrated a reduction in ARR and EDSS. Prospective studies 
comparing combination therapy, sequential therapy and induction therapy will be needed to 
balance benefits and risks.
Selection of therapies
Although no prospective clinical trials have been conducted in NMO, retrospective and 
prospective case series have been used to develop a framework to guide treatment decisions. 
Owing to the more-extensive availability of clinical data, azathioprine, mycophenolate 
mofetil and rituximab tend to be the most-recommended first-line therapies for NMO 
prophylaxis. Second-line therapies include methotrexate, mitoxantrone and cyclosporine. 
Due to the potential toxicity of mitoxantrone and the limited clinical data on methotrexate 
and cyclosporine, physicians should consider restricting their use to refractory cases. Certain 
emerging therapies could also be considered for off-label use in patients with refractory 
NMO; however, long-term safety issues remain of particular concern.
Special circumstances
Pregnancy—NMO exacerbations are not substantially increased during pregnancy; 
however, the frequency of exacerbations increases in the postpartum period and during the 
year following childbirth.85,86 In relation to pregnancy, the FDA classifies drugs as category 
A (no adverse effect on fetus in human trials), B (no adverse effect on fetus in animal 
studies), C (adverse effects on fetus in animal studies without good data from human 
studies), D (adverse effects on fetus in human studies) and X (adverse effects on fetus in 
human and animal studies). Azathioprine, mycophenolate and methotrexate are pregnancy 
category D or X and should not be continued during pregnancy. Although rituximab and 
prednisone are pregnancy class C, the absence of an increase in ARR during pregnancy 
makes continued therapy during pregnancy questionable unless the patient displays evidence 
of renewed disease activity. Given the increased relapse rate following delivery, rapid 
introduction of prophylactic therapy could be warranted; however, the benefits of these 
therapies should be balanced against the benefits of breastfeeding. Ringelstein et al.87 
reported an uneventful pregnancy in an AQP4-IgG-seropositive NMO patient who received 
low-dose rituximab (100 mg) 7 months before pregnancy without complications to the 
mother or newborn. Interestingly, despite a low rituximab dosage, the newborn’s umbilical 
cord blood showed decreased CD19+ B cells and evidence of adoptive transfer of AQP4-
IgG.
Fetal and paediatric NMO—Unlike the CNS of fetal rodents, which express little or no 
AQP4,88 the human fetal CNS strongly expresses AQP4,89,90 thus raising the possibility that 
AQP4-IgG might attack the human fetal CNS. To date, no published evidence is available to 
support this hypothesis. Both mouse and human placenta also express AQP4,90–92 and 
intraperitoneal administration of AQP4-IgG in pregnant mice caused dose-dependent 
placental inflammation and spontaneous abortion.90 In addition, one case of AQP4-IgG 
attacking the placenta causing spontaneous abortion in humans has been reported.93 Several 
case studies have reported normal pregnancies in women receiving treatment for 
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NMO.87,94,95 Overall, it is unclear whether the effects of maternal NMO on the 
fetoplacental unit in humans are sufficient to justify treatment in the presence of AQP4-IgG, 
but without active maternal disease.
Although children as young as 2 years96 can develop NMO, the median age of children 
presenting with the disease is 10–14 years.97 Children with NMO have been suggested to be 
more likely to be seronegative and to have brain involvement than adult patients.98–100 
Therapies for children are similar to those used in adults, with IVMP and plasma exchange 
for an acute attack, and long-term immunosuppression to prevent relapses.
MS treatments that worsen NMO—Several MS therapies have poor efficacy or adverse 
effects in NMO. IFN-β increases relapse rate101 and promotes severe exacerbations,102–104 
possibly by increasing production of BAFF and IL-17.105
Natalizumab, an antibody against very late antigen-4, has been reported to have no effect or 
to worsen disease activity in AQP4-IgG-seropositive106,107 and AQP4-IgG-seronegative108 
patients with NMO. A small study of five patients with NMO treated with natalizumab 
reported nine relapses and an increase in mean EDSS from 4.0 to 7.0.109 Lesions observed 
during natalizumab treatment show florid active demyelination, severe neutrophilic and 
eosinophilic infiltrates, and severe astrocyte loss.107 Natalizumab can accelerate disease 
activity by increasing the numbers of peripheral proinflammatory T cells or eosinophils.110 
Peripheral eosinophils might be able to migrate to the CNS and exacerbate lesion 
formation111,112 or facilitate stabilization of AQP4-specific bone marrow plasma cells.113
Oral fingolimod has also been reported to cause an increase in NMO disease activity. In two 
studies,114,115 fulminant disease activity was observed quickly after the initiation of therapy. 
Like natalizumab, fingolimod promotes bone marrow egress of eosinophils116 and might 
thereby enhance lesion activity and AQP4-IgG production.
Drugs with potential for repurposing
Improved understanding of the mechanisms of NMO pathogenesis has led to discovery of 
novel therapeutic targets (Figure 2). In this section, we discuss the potential for repurposing 
of approved therapeutics in NMO, including some approaches that are currently undergoing 
clinical trials (Table 2).
Complement-targeted therapy
As discussed above, complement activation seems to be involved in NMO pathogenesis. In 
cultured cells, AQP4-IgG binds AQP4 and activates complement via the classical pathway, 
resulting in cell lysis.3 In mouse spinal cord tissue slices35 and in vivo mouse models,33 
complement activation is required for AQP4-IgG to cause the characteristic histological 
changes comprising loss of AQP4 and glial fibrillary acidic protein, inflammatory cell 
infiltration, and demyelination.
The C5 complement inhibitor eculizumab, which is approved for use in paroxysmal 
nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, has recently been 
tested in NMO in an open-label trial.117 Eculizumab is a humanized IgG2/4 antibody that 
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binds C5 and inhibits its cleavage into C5a and C5b. AQP4-IgG-seropositive patients with 
NMOSD who had experienced at least two attacks in the preceding 6 months or three in the 
previous 12 months received 600 mg intravenous eculizumab weekly for 4 weeks, 900 mg in 
the fifth week, and then 900 mg every 2 weeks for 48 weeks. In the 14 patients studied, 
eculizumab significantly reduced attack frequency, and stabilized or improved neurological 
disability measures. The main drawbacks of eculizumab are its high cost (around US
$400,000 per patient-year), and risk of meningococcal sepsis, which was seen in one patient 
in the trial. Given these disadvantages, testing the safety and efficacy of eculizumab for 
acute NMO relapses could be worthwhile.
IL-6 receptor-targeted therapy
Interleukin-6 (IL-6) has been implicated as a driver of NMO disease activity.118 
Cerebrospinal fluid (CSF) IL-6 and soluble IL-6 receptor levels are elevated in NMO during 
an attack,119,120 and the plasma cell population in the blood and CSF expands during NMO 
relapse.31 In vitro, IL-6 enhances the survival of these cells and increases AQP4-IgG 
secretion, whereas blockade of the IL-6 receptor reduces their survival.118 Several case 
reports121–124 show reduced relapse rate in NMO patients treated with tocilizumab, a 
humanized murine anti-IL-6 receptor monoclonal antibody. Another anti-IL-6 receptor 
monoclonal antibody, SA237, which has a fourfold greater duration of action than 
tocilizumab, has recently entered a clinical trial in NMO.
Granulocyte-targeted therapies
One of the major histological differences between MS and NMO lesions is the presence of 
perivascular neutrophils, as reported in patients with NMO111 as well as in mouse33,37 and 
rat125 models of the condition. Neutrophil counts are elevated in the CSF of about 60% of 
untreated patients during relapse, but only in about 20% of patients during remission.126 In 
mouse models of NMO37 and in mouse spinal cord slices,35 elimination of neutrophils 
ameliorates tissue damage, whereas increased neutrophil counts enhance tissue damage. 
Inadvertent administration of granulocyte colony-stimulating factor in a patient with NMO 
was found to be detrimental.127
Sivelestat, a small-molecule inhibitor of neutrophil elastase, which is involved in neutrophil 
migration128 and neutrophil-mediated tissue damage,128,129 reduced NMO pathology in a 
mouse model of NMO.30 Sivelestat was originally developed to treat acute respiratory 
distress syndrome and is approved for that purpose in Japan.130 Sivelestat is well tolerated, 
but has a short half-life of 6 h, thus requiring continuous infusion to maintain therapeutic 
levels.131 Studies in animal models of NMO suggest that neutrophil entry into the CNS 
occurs early (within 24 h of lesion initiation),37 whereas macrophages might predominate at 
later stages. The pathological observations and animal data suggest the utility of sivelestat in 
an acute NMO attack, which is being tested in a small clinical trial in Japan.
In addition to neutrophils, eosinophils are found in inflammatory demyelinating lesions in 
NMO, but are absent in MS.111 Postulating that eosinophil inhibitors could be useful in 
NMO, researchers initiated a series of in vitro and in vivo studies to investigate the role of 
eosinophils in NMO pathogenesis and the efficacy of eosinophil inhibitors in reducing NMO 
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pathology.112 Eosinophils cultured from mouse bone marrow produced robust AQP4-IgG-
dependent ADCC in AQP4-expressing cells and spinal cord slice cultures and, in the 
presence of complement, eosinophils produced complement-dependent cellular cytotoxicity 
(CDCC). NMO-like pathology was also produced in spinal cord slice culture by eosinophil 
granule toxins, suggesting that eosinophil degranulation contributes to NMO pathogenesis.
The second-generation antihistamines cetirizine and ketotifen, which have eosinophil-
stabilizing actions,132 were found to greatly reduce cytotoxicity mediated by AQP4-IgG and 
eosinophils.112 In mice, demyelinating NMO lesions with marked eosinophil infiltration 
were produced by continuous intracerebral injection of AQP4-IgG and complement. Lesion 
severity was increased in transgenic hypereosinophilic mice, and was reduced in mice made 
hypo-eosinophilic by an anti-IL-5 antibody or by gene deletion, and in normal mice 
receiving cetirizine orally. Cetirizine is currently being tested in patients with NMO in a 
small clinical study. Alternative agents that reduce eosinophil numbers or activity could also 
be useful in NMO.
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIg) is another approved therapy with potential for 
repurposing in NMO. IVIg, which consists of pooled human IgG from more than 1,000 
blood donors and is administered to the circulation of the patient, has been used for over 30 
years to treat idiopathic thrombocytopenic purpura,133 and has been used to treat various 
immune-mediated demyelinating diseases of the nervous system including Guillain-Barré 
syndrome, chronic inflammatory demyelinating polyneuropathy, diabetic polyneuropathy, 
multifocal motor neuropathy, and myasthenia gravis.134 IVIg has pleiotropic actions on the 
immune system, including autoantibody neutralization, blockade of antibody–target binding, 
acceleration of autoantibody clearance, inhibition of dendritic cell activation and leukocyte 
migration, complement inhibition, and blocking of Fcγ receptors.135
The data supporting the clinical benefit of IVIg in NMO are limited. In one study, IVIg 
showed efficacy in the prevention of relapses in eight NMO patients, with a reduction in 
mean ARR from 1.8 in the year before IVIg treatment to 0.006 during a mean follow-up of 
19.3 months.136 Other case studies also support a beneficial effect of IVIg in preventing 
relapse in NMO,137,138 and potentially in acute NMO relapses.61 In a proof-of-concept 
study, AQP4-IgG was administered to rats by intracerebral injection, and the size of the 
resulting neuroinflammatory demyelinating lesions was reduced by about 50% when IVIg 
was subsequently administered by intraperitoneal injection to yield serum levels of 10–25 
mg/ml IgG, which is comparable to human therapeutic levels.139 In vitro studies suggested 
that inhibition of AQP4-IgG-mediated CDC and ADCC were the primary mechanisms 
mediating the beneficial effects found in vivo. Further evaluation of IVIg in NMO thus 
seems warranted.
CD19-targeted therapy
Bone marrow-derived and tissue-resident AQP4-IgGexpressing plasma cells are considered 
to be the source of circulating AQP4-IgG in seropositive patients, and numbers of peripheral 
blood plasmablasts capable of producing AQP4-IgG are increased in the CSF and peripheral 
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blood of relapsing patients with NMO.34,118 CD19 is a B-cell surface marker that is 
expressed on the surface of plasmablasts and some plasma cells140 and might provide an 
alternative target for B-cell-depletive therapy in NMO. Owing to the expression of CD19 on 
some antibody-producing cell populations, antibodies targeted against this antigen might 
diminish serum titres of AQP4-IgG and reduce levels of circulating plasmablasts that can 
contribute to intrathecal inflammation.80 Several CD19-targeted therapies are currently 
under active investigation, 141 and could potentially be rapidly repurposed for clinical trials 
in NMO.
TNF-targeted therapy
Many of the therapies currently used for preventing NMO relapses, such as azathioprine, 
mycophenolate mofetil, methotrexate, and rituximab, are used for the treatment of 
rheumatoid arthritis. The success of these agents in both NMO and rheumatoid arthritis 
suggests that some critical immunopathology is shared between these autoimmune disorders.
Anti-tumour necrosis factor (TNF) therapies are central to the modern-day treatment of 
rheumatoid arthritis and could potentially be repurposed for the treatment of NMO. Addition 
of TNF to an ex vivo NMO spinal cord slice model has been demonstrated to exacerbate 
AQP4-IgG-mediated tissue injury.35 TNF might also impede lesion repair through 
oligodendrocyte precursor cell toxicity.142 Anti-TNF therapies could, therefore, offer a 
novel avenue for treatment of acute NMO attacks. Since serum levels of TNF are not 
elevated in patients with NMO,143 however, anti-TNF therapies might have limited in use in 
the prevention of exacerbations.
Novel therapies in the pipeline
Blockade of AQP4-IgG–AQP4 binding
Several therapeutic approaches have been developed to block the binding of AQP4-IgG to 
AQP4, thereby reducing CDC, ADCC and downstream pathogenicity (Table 3). In one 
approach, a nonpathogenic human monoclonal antibody, aquaporumab, was generated from 
a recombinant monoclonal AQP4-IgG that binds tightly to AQP4. Mutations were 
introduced into the Fc region of the antibody to eliminate its CDC and ADCC effector 
functions (Figure 3).144 Aquaporumab competitively displaces AQP4-IgG in the serum of 
patients with NMO, in part by steric hindrance, because the IgG1 antibody is large 
compared with the AQP4 tetramer (Figure 3).Aquaporumab greatly reduced AQP4-IgG-
dependent cytotoxicity and NMO pathology in animal and in vitro models of NMO.144 As 
targeting of AQP4 by aquaporumab is highly selective, immunosuppression should not 
occur and minimal toxicity is anticipated, although as with any biological drug, studies are 
needed to exclude off-target effects and immunogenicity. Aquaporumab is currently in 
preclinical development.144
In an alternative approach, a target-based small-molecule screen identified several potential 
drugs and natural products that reduced AQP4-IgG binding to AQP4 by binding to the 
extracellular surface of AQP4; these agents included the antiviral agent arbidol and the 
neutraceutical berbamine.145 Screens also identified idiotype-selective compounds that bind 
to the variable region of monoclonal AQP4-IgG.146 The compounds identified so far have 
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relatively weak affinity for AQP4 and unfavourable pharmacological properties for use in 
NMO, so more-extensive screening might be required to identify further small-molecule 
drug candidates. The level of plasma membrane AQP4 expression and its supramolecular 
assembly in orthogonal arrays of particles (OAPs) are important determinants of AQP4-IgG 
pathogenicity,147–150 so targeting of astrocyte AQP4 expression at the transcriptional or 
post-translational levels would be predicted to be beneficial in NMO, as would targeting of 
OAP formation by AQP4. Whether selective drug-like regulators of AQP4 expression or 
assembly can be identified, however, is currently unclear.
Antibody inactivation
Antibody inactivation is considered to be a potential therapeutic approach for autoimmune 
diseases caused by pathogenic antibodies. Several bacterial enzymes selectively target IgG-
class antibodies. Some of these enzymes interfere with the binding site for complement 
component C1q on the antibody, thereby neutralizing the Fc effector functions that are 
involved in CDC, whereas others target the Fcγ receptor binding motif that is involved in 
ADCC. One such enzyme, endoglycosidase S (EndoS), is a 108 kDa protein, derived from 
Streptococcus pyogenes, that selectively digests asparagine-linked glycans on IgG heavy 
chains (Figure 3).151 The enzymatically deglycosylated antibody has virtually no 
cytotoxicity effector functions. In a proof-of-concept study, treatment of serum from NMO 
patients with EndoS prevented CDC and ADCC in vitro, and counteracted the development 
of NMO pathology in vivo in animal models.152 The deglycosylated antibody also 
competitively displaced pathogenic NMO-IgG bound to AQP4, thus converting pathogenic 
AQP4-IgG into a therapeutic blocking antibody.
Another S. pyogenes-derived enzyme, IgG-degrading enzyme (IdeS), selectively cleaves 
IgG antibodies to yield Fc and F(ab′)2 fragments.148 As found with EndoS, IdeS treatment 
of NMO patient serum abolished CDC and ADCC in vitro and NMO pathology in vivo.153 
Notwithstanding the challenges related to IgG inactivation kinetics, manufacturing, and 
effects of general IgG neutralization, EndoS or IdeS treatment of blood by therapeutic 
apheresis using surface-immobilized enzyme might be useful in NMO. The blocking activity 
of nonpathogenic AQP4-IgG fragments in EndoS-treated or IdeS-treated blood could confer 
additional therapeutic benefit over that obtained with plasma exchange.
Other complement-targeted therapies
Motivated by the central role of complement activation in NMO pathogenesis and the initial 
success of C5 inhibition by eculizumab, as discussed above, other complement-targeted 
therapeutics are under consideration in NMO (Figure 4). The infectious adverse effects of 
eculizumab are thought to result from inhibition of the lectin pathway and alternative 
complement activation pathway, which are necessary for killing bacteria.154 C1-targeted 
monoclonal antibodies have been shown to be efficient in both in vitro and in vivo models of 
NMO.155 In contrast to C5 inhibition, C1 inhibition has multiple therapeutic effects: it 
prevents the generation of C3a and C3b, which participate in CDCC by causing effector cell 
chemotaxis, binding and degranulation; prevents amplification of the classical complement 
pathway by the alternative complement pathway; and does not interfere with defence against 
bacteria because the lectin and alternative activation pathways remain intact. Selective 
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inhibition of the classical complement pathway in NMO is, thus, predicted to be superior to 
generalized complement inhibition. Alternative agents that might be useful in NMO include 
a peptide inhibitor of C1 esterase activity (C1inh), a cyclic oligopeptide targeting C3 
(compstatin), inhibitors of C3a and C5a receptors, and monoclonal antibodies and small 
molecules against other complement components, which are currently under development 
(Figure 4).156,157
Complement inhibitor CD59
Another potentially attractive target in NMO is CD59, the major complement inhibitor 
protein in astrocytes. CD59 is a glycophosphoinositol-anchored membrane protein that 
inhibits formation of the terminal C5b–9 membrane attack complex.158 Other complement 
inhibitor proteins that might be present in astrocytes, albeit to a lesser extent, include CD55 
(also called decay acceleration factor), CD46 (membrane cofactor protein) and CD35 (type 1 
complement receptor).159 Various human diseases, including atypical haemolytic uraemic 
syndrome, membranoproliferative glomerulonephritis, C3 glomerulonephritis and dense 
deposit disease, involve mutation or dysregulation of complement regulatory proteins.160 
Pharmacological upregulation of CD59 or other complement inhibitors on astrocytes is be 
predicted to be beneficial in NMO by reducing AQP4-IgG-dependent CDC. In two proof-of-
concept studies in mouse models of NMO created by passive transfer of AQP4-IgG,161,162 
CD59 deletion or neutralization greatly increased NMO pathology in the spinal cord, optic 
nerve and brain. Small-molecule screening might yield upregulators of astrocyte CD59 
expression that are of potential therapeutic value in NMO.
Antibody-dependent cellular cytotoxicity
Although CDC has a central role in NMO pathogenesis, an expanding body of evidence also 
indicates an important role for ADCC, which involves binding of AQP4-bound AQP4-IgG 
to Fcγ receptors on effector cells, causing their accumulation, phagocytosis and 
degranulation. In addition to in vitro studies showing AQP4-IgG-dependent ADCC by 
granulocytes and natural killer cells,163 in vivo evidence from rodent models demonstrates 
ADCC-initiated NMO pathology,36,125 as well as involvement of AQP4-IgG ADCC effector 
function in the initiation of NMO pathology.38 Administration of a neutralizing FcγIII-
receptor antibody reduced NMO pathology in a mouse model.38 Notwithstanding the 
complexity of Fcγ receptor expression on human effector cells,164 targeting of Fcγ receptors 
using antibodies or small molecules might have therapeutic benefit in NMO.
Targeting the blood–brain barrier
Targeting of the blood–brain barrier could be beneficial in NMO. Two in vitro studies28,163 
have reported that serum from AQP4-IgG-seropositive patients increases permeability of 
human astrocyte–endothelial cell cocultures and reduces expression of tight junction 
proteins in cultured brain microvascular endothelial cells, thereby recapitulating the 
mechanisms involved in blood–brain barrier opening. Dysfunction of the blood– brain 
barrier—detected as raised albumin levels in CSF or blood—was more common in patients 
with NMO during relapse than during remission (55% versus 33% of patients), and CSF and 
blood albumin levels were significantly increased during a relapse.126 Although the 
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mechanisms are unclear, the secretion of vascular endothelial growth factor (VEGF) by 
astrocytes or endothelial cells has been suggested to be involved.28 The matrix 
metalloproteinase MMP-9, levels of which are elevated in the serum of patients with 
NMO,165 might be released from neutrophils in the NMO lesion and degrade the blood– 
brain barrier basement membrane. The humanized murine monoclonal antibody 
bevacizumab, a VEGF inhibitor, is currently in a clinical trial to determine whether it 
reduces blood–brain barrier opening in NMO.
Tolerance and transplantation
Antigen-specific tolerance against AQP4 provides a novel approach for suppression of the 
immune response in NMO. AQP4 tolerance could effectively halt the pathological immune 
response that drives CNS tissue injury while leaving the remainder of the immune 
surveillance system intact. Methods for inducing antigen-specific tolerance include DNA 
vaccination, altered peptide ligands, and low-dose oral or nasal antigen administration.166 In 
MS, initial attempts at antigen-induced tolerance either failed to produce clinical 
efficacy167,168 or worsened disease activity.169 The failure of antigen-specific therapy in MS 
could be related in part to the lack of a definitive disease-specific antigen in affected 
individuals, and similar strategies targeting AQP4 in seropositive NMO might yield more-
substantial clinical and immunological effects.
An alternative and aggressive strategy for restoring immune tolerance in NMO is autologous 
haematopoietic stem cell transplantation (HSCT). HSCT has shown benefit in the treatment 
of severe MS170 and systemic lupus erythematosus,171 and aggressive cases of NMO might 
demonstrate a similar robust and prolonged response. Owing to the considerable mortality 
associated with HSCT, however, careful selection of cases is mandatory.
Challenges and future directions
Clinical trials
The burgeoning environment of NMO therapeutics mandates clinical studies that provide 
definitive evidence of efficacy. These future clinical trials, however, present substantial 
challenges. First, the potential severity of NMO disease activity can limit the ability of 
investigators to accumulate extensive longitudinal data. Second, there are no defined criteria 
for clinical end points in NMO trials. Third, the number of potential trial participants is 
limited, necessitating the incorporation of sensitive primary end points. Last, there are 
concerns in trials designs involving a placebo arm because untreated NMO produces 
irreversible neurological deficits. The landscape is further complicated by the lack of a 
definitive preventative therapy, requiring investigators to try to balance the increased 
enrolment requirements of active comparator trials with the potential safety concerns 
associated with immunosuppressant or placebo therapy. Eventually, NMO clinical trials will 
need to address the above issues within an experimental design that allows regulators to 
determine the definitive risks and benefits of the investigational agent. Currently, NMO 
clinical trials are focused on preventative therapy and use time to first relapse as the primary 
end point. Future prophylactic trials will need to incorporate additional metrics to assess 
NMO relapse severity and progressive disability to begin to differentiate the entire spectrum 
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of therapeutic efficacy. In addition, NMO clinical trials will need to focus on the evaluation 
of acute therapeutics and the development of new clinical metrics for evaluation of relapse 
recovery.
Seronegative NMO
Management of AQP4-IgG-seronegative patients poses a challenge, because it is currently 
unclear whether their disease is caused by an AQP4-IgG-like antibody that recognizes an 
antigen different from AQP4, or whether these patients have a different disease altogether 
that shares clinical features with seropositive NMO. No animal models of AQP4-IgG-
seronegative NMO currently exist. Several studies172–177 have reported IgG antibody 
against myelin oligodendrocyte glycoprotein (MOG-IgG) in the serum of 10–15% of 
patients with AQP4-IgG-seronegative NMO. The MOG-IgG-positive patients often have 
better clinical outcomes than the AQP4-IgG-seropositive patients, including resolution of 
their radiological abnormalities. The role of MOG-IgG in NMO disease pathogenesis is 
unclear,178 although a recent study179 reported that NMO MOG-IgG injected in the mouse 
brain causes changes in the expression of axonal proteins that are required for the integrity 
of the nodes of Ranvier and normal action potential firing. Interestingly, MOG-IgG did not 
produce inflammation in this model, and the tissue changes were independent of 
complement activation. Unlike AQP4-IgG-induced damage in the mouse brain, which was 
complement-dependent and irreversible, the MOG-IgG-induced changes disappeared within 
2 weeks. The differences in lesion pathology and recovery are reflected in the clinical 
outcomes of MOG-IgG+ NMO and AQP4-IgG+ NMO patients.173–177 Further studies are 
needed to understand the pathogenesis of seronegative NMO, and to determine whether 
MOG-IgG+ NMO is pathologically related to or is a phenocopy of AQP4-IgG+ NMO.
Conclusions
In summary, the NMO therapeutics pipeline is quite full, with approved drugs being 
evaluated for repurposing in NMO, and new agents targeting a wide range of pathways in 
disease pathogenesis. Development of effective, highly selective drug therapy without 
general immunosuppression or off-target toxicity is a central goal in NMO therapeutics. 
Despite the inherent challenges of future clinical trials in NMO, such as patient enrolment 
and clinical variability, significant advances in treatment of NMO are anticipated.
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Key points
• Most patients with neuromyelitis optica (NMO) have serum IgG antibodies 
against astrocytic aquaporin-4 (AQP4) channels, a minority have antibodies to 
myelin oligodendrocyte glycoprotein, and some have neither
• Current NMO treatments include corticosteroids and plasma exchange, which 
reduce the severity of acute attacks, and prednisolone, rituximab, 
cyclophosphamide, azathioprine, mycophenolate, mitoxantrone, methotrexate 
and cyclosporine, which prevent relapses
• Some multiple sclerosis treatments, such as IFN-β, fingolimod and natalizumab, 
can be harmful in NMO
• Approved therapies with potential for repurposing in NMO include eculizumab 
(complement inhibitor), tocilizumab (IL-6 receptor inhibitor), sivelestat and 
cetirizine (granulocyte inhibitors), intravenous immunoglobulin, CD19-
depleting agents, and anti-TNF therapy
• Potential therapeutic approaches include inhibition of AQP4-IgG binding 
(aquaporumab, small molecules), AQP4-IgG inactivation (endoglycosidase S, 
IgG-degrading enzyme), alternative complement inhibitors (C1inh, compstatin, 
CD59), anti-FcγRIII antibody, VEGF inhibition (bevacizumab), and antigen-
specific tolerization
• Challenges for NMO therapeutics include optimization of drug penetration into 
NMO lesions, clinical trial design (given the small patient numbers), and 
management of seronegative patients
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Review criteria
We searched PubMed (all years) using the search terms “NMO”, “neuromyelitis optica” 
and “aquaporin-4”. We also read abstracts from the Guthy-Jackson Charitable 
Foundation NMO and the ECTRIMS meetings (2009–2013).
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Figure 1. 
Mechanisms of NMO pathogenesis. Serum AQP4-IgG and plasma cells that produce AQP4-
IgG penetrate the CNS, resulting in binding of AQP4-IgG to AQP4 channels on astrocytes. 
Antibody-dependent astrocyte damage involving complement-dependent cytotoxicity, 
CDCC and ADCC mechanisms lead to inflammation, oligodendrocyte injury, demyelination 
and neuronal loss. The CD59 glycoprotein inhibits cell lysis by inhibiting formation of the 
MAC. Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; AQP4, aquaporin-4; 
CDC, complement-dependent cytotoxicity; CDCC, complement-dependent cellular 
cytotoxicity; MAC, membrane attack complex; NMO, neuromyelitis optica.
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Figure 2. 
Pharmacological targets in NMO. Green boxes show mechanism-based approches currently 
used to treat NMO (anti-CD20 antibody [rituximab]; immunosuppressive agents; plasma 
exchange), purple boxes show approved drugs under evaluation for repurposing for NMO, 
blue boxes show drugs in preclinical development, and orange boxes show pharmacological 
intervention strategies at early, proof-of-concept stage. See Table 1 for additional 
information. Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; AQP4, 
aquaporin-4; CDC, complement-dependent cytotoxicity; IVIg, intravenous immunoglobulin; 
NMO, neuromyelitis optica.
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Figure 3. 
AQP4-IgG blocking and inactivation strategies for NMO therapy. An AQP4 array with 
bound AQP4-IgG antibody is shown in the middle of the figure. High-affinity, 
nonpathogenic anti-AQP4 antibody (aquaporumab) competes with pathogenic AQP4-IgG 
for AQP4 binding. Streptococcus pyogenes-derived enzymes IdeS and EndoS selectively 
inactivate IgG through proteinase and endoglycosidase actions, respectively, producing 
blocking nonpathogenic antibody remnants. Abbreviations: ADCC, antibody-dependent 
cellular cytotoxicity; AQP4, aquaporin-4; C1q, complement component C1q; CDC, 
complement-dependent cytotoxicity; CDCC, complement-dependent cellular cytotoxicity; 
CL, constant region of light chain; EndoS, endoglycosidase S; Fab, fragment antigen-
binding region; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; IdeS, IgG-
degrading enzyme; Man, mannose; NMO, neuromyelitis optica; Sial, sialic acid; VH, 
variable region of heavy chain; VL, variable region of light chain.
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Figure 4. 
Complement activation pathways and complement drug targets. The major components of 
the classical, alternative and lectin complement activation pathways are shown, along with 
C1mAb and eculizumab—monoclonal antibodies that target complement components C1 
and C5, respectively; C1inh, which targets C1; and the cyclic oligopeptide compstatin, 
which targets C5. C3a and C5a anaphylatoxins cause granulocyte activation by binding to 
specific receptors. Abbreviations: AQP4, aquaporin-4; C1inh, complement protein 1 
inhibitor; MAC, membrane attack complex; MASP, mannan-binding lectin serine protease; 
MBL, mannose-binding protein.
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Table 1
Commonly used NMO treatments in adults
Treatment Typical dose Mode of action
For acute exacerbation
Methylprednisolone60 1 g daily, for 3–5 days Multiple
Plasma exchange57–60 Five to seven cycles Depletion of AQP4-IgG and cytokines
Intravenous immunoglobulin61,136 0.7g/kg for 3 days; treatment period 8 weeks Multiple
Cyclophosphamide62 2 g daily for 4 days Inhibits mitosis
Relapse rate reduction
Prednisolone64 2–20 mg daily Multiple
Rituximab74–80,180,181 For example, 1 g at day 1 and day 14, repeat every 
6 months (optional: monitoring of CD19 counts)
Anti-CD20, B-cell depletion
Plasma exchange65 Immunosuppression Depletion of AQP4-IgG and cytokines
Cyclophosphamide 2 g daily for 4 days Inhibits mitosis
Azathioprine66–68,180 2.5–3.0 mg/kg daily Blocks synthesis of adenine and guanine
Mycophenolate69,180 750–3000 mg daily Inhibits inosine monophosphate dehydrogenase, 
primarily the type II isoform found in T cells and 
B cells
Mitoxantrone71,182 Initiation with 12 mg/m2 monthly for 3–6 months, 
maintenance with 6–12 mg/m2 every 3 months; 
maximum cumulative dose of 120 mg/m2
Intercalates DNA, inhibits mitosis
Methotrexate70 7.5–25 mg once weekly Folic acid antagonist
Cyclosporine A84 2–5 mg/kg daily Inhibits T cells
Harmful in NMO or insufficient safety data
IFN-β101–104 NA Harmful in NMO
Fingolimod114,115 NA Might be harmful in NMO (insufficient data)
Natalizumab106,107 NA Might be harmful in NMO (insufficient data)
Abbreviations: AQP4, aquaporin-4; CD20, B-lymphocyte antigen CD20; NA, not applicable; NMO, neuromyelitis optica.
Nat Rev Neurol. Author manuscript; available in PMC 2014 November 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Papadopoulos et al. Page 32
Ta
bl
e 
2
Cu
rre
nt
 th
er
ap
eu
tic
 tr
ia
ls 
in
 N
M
O
C
om
pa
ny
In
te
rv
en
tio
n
M
od
e 
of
 a
ct
io
n
Ty
pe
 o
f t
ri
al
R
ec
ru
itm
en
t
Pu
rp
os
e 
of
 tr
ia
l
A
le
xi
on
Ec
ul
iz
um
ab
 (S
oli
ris
®
)
In
hi
bi
ts 
C5
Ph
as
e 
III
N
ot
 y
et
 st
ar
te
d
Lo
ng
-te
rm
 sa
fe
ty
 a
nd
 e
ffi
ca
cy
 fo
r r
el
ap
se
 ra
te
 re
du
ct
io
n 
in
 A
QP
4-
Ig
G
+
 
N
M
O
N
ih
on
In
tra
ve
no
us
 im
m
un
og
lo
bu
lin
 (N
PB
-01
) c
om
bin
ed
 w
ith
 
st
er
oi
ds
M
ul
tip
le
Ph
as
e 
II
R
ec
ru
iti
ng
Sa
fe
ty
 a
nd
 e
ffi
ca
cy
 in
 A
QP
4-I
gG
+
 
N
M
O
M
ay
o 
Cl
in
ic
Pl
as
m
a 
ex
ch
an
ge
Ig
G
 d
ep
le
tio
n
Ph
as
e 
I
R
ec
ru
iti
ng
Fe
as
ib
ili
ty
, t
ol
er
ab
ili
ty
, s
af
et
y 
an
d 
pr
el
im
in
ar
y 
ef
fic
ac
y 
as
 
m
ai
nt
en
an
ce
 th
er
ap
y 
in
 N
M
O
V
iro
ph
ar
m
a
C1
in
h 
(C
inr
yz
e®
) a
s a
n a
dd
-on
 th
era
py
C1
 in
hi
bi
tio
n
Ph
as
e 
I
Co
m
pl
et
ed
To
le
ra
bi
lit
y,
 sa
fe
ty
 a
nd
 p
re
lim
in
ar
y 
ef
fic
ac
y 
in
 a
cu
te
 N
M
O
/N
M
O
SD
G
en
en
te
ch
B
ev
ac
iz
um
ab
 (A
va
sti
n®
) a
s a
dd
-on
 th
era
py
In
hi
bi
ts 
V
EG
F
Ph
as
e 
II
N
ot
 y
et
 st
ar
te
d
To
le
ra
bi
lit
y,
 sa
fe
ty
 a
nd
 p
re
lim
in
ar
y 
ef
fic
ac
y 
in
 a
cu
te
 N
M
O
/N
M
O
SD
Ch
ug
ai
SA
23
7
A
nt
i-I
L-
6 
re
ce
pt
or
Ph
as
e 
III
N
ot
 y
et
 st
ar
te
d
Sa
fe
ty
, e
ffi
ca
cy
; p
ha
rm
ac
od
yn
am
ic
, p
ha
rm
ac
ok
in
et
ic
 a
nd
 
im
m
un
og
en
ic
 p
ro
fil
es
 in
 N
M
O
/N
M
O
SD
O
N
O
Si
ve
le
sta
t (
El
asp
ol®
) c
om
bin
ed
 w
ith
 m
eth
ylp
red
nis
olo
ne
A
nt
i-n
eu
tro
ph
il
Ph
as
e 
I, 
II
R
ec
ru
iti
ng
Sa
fe
ty
 a
nd
 e
ffi
ca
cy
 in
 a
cu
te
 N
M
O
G
en
en
te
ch
To
ci
liz
um
ab
 (A
cte
mr
a®
,
 
To
ac
te
m
ra
®
)
A
nt
i-I
L-
6 
re
ce
pt
or
Ph
as
e 
I, 
II
Co
m
pl
et
ed
Sa
fe
ty
 a
nd
 e
ffi
ca
cy
 in
 in
tra
ct
ab
le
 N
M
O
; e
xp
lo
ra
tio
n 
of
 m
ec
ha
ni
sm
s 
o
f a
ct
io
n
A
bb
re
vi
at
io
ns
: A
QP
4, 
aq
ua
po
rin
-4;
 A
QP
4-I
gG
+
,
 
A
QP
4-I
gG
-se
rop
os
itiv
e; 
C,
 co
mp
lem
en
t p
rot
ein
; N
M
O,
 ne
uro
my
eli
tis
 op
tic
a; 
NM
OS
D,
 N
M
O 
sp
ec
tru
m 
dis
ord
er;
 V
EG
F, 
va
scu
lar
 en
do
the
lia
l g
row
th 
fa
ct
or
.
Nat Rev Neurol. Author manuscript; available in PMC 2014 November 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Papadopoulos et al. Page 33
Table 3
Compounds in the pipeline
Compound Target molecule Mechanism of action
Anti-CD1934,118 B-cell surface marker Depletion of naive and memory B cells, plasmablasts, and some plasma cells
Anti-IL-1754,183 Cytokine Blocks IL-17 signal transduction
Aquaporumab144 AQP4 Binds to AQP4 on CNS astrocytes and blocks AQP4-IgG binding
IdeS153 AQP4-IgG Cleaves circulating AQP4-IgG
EndoS152 AQP4-IgG Deglycosylates AQP4-IgG to eliminate CDC and ADCC function
Small-molecule blockers145 AQP4-IgG Competitive inhibition of AQP4-IgG binding
Peptoid inhibitors184 AQP4-IgG Competitive inhibition of AQP4-IgG binding
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; AQP4, aquaporin-4; CDC, complement-dependent cytotoxicity; NMO, 
neuromyelitis optica.
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